MedTrace Logo

Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis

NCT00606450 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2020-04-24

No results posted yet for this study

Summary

There is an unmet medical need for safe, effective oral therapy for moderate-to-severe psoriasis. CC-10004 will be evaluated in a controlled setting of a clinical study. The information obtained from the study will aid in the design of future clinical trials and to establish the safety and efficacy of CC-10004.

Conditions

Interventions

DRUG

CC-10004

20 mg CC-10004 taken 1 time per day for 12 weeks

DRUG

CC-10004

20 mg of CC-10004 taken 2 times per day for 12 weeks

DRUG

Placebo

matching placebo taken either 1 or 2 times per day for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-01
Primary Completion
2007-02-01
Completion
2007-05-01

Countries

  • Canada
  • Czechia
  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00606450 on ClinicalTrials.gov